Protalix Biotherapeutics (NYSEAMERICAN:PLX) Trading Down 3.4%

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) dropped 3.4% during mid-day trading on Monday . The company traded as low as $0.26 and last traded at $0.28, approximately 10,947 shares were traded during mid-day trading. A decline of 98% from the average daily volume of 556,246 shares. The stock had previously closed at $0.29.

PLX has been the subject of a number of research reports. HC Wainwright set a $3.00 price objective on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a report on Friday. Zacks Investment Research upgraded shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The firm had revenue of $12.25 million for the quarter, compared to the consensus estimate of $11.75 million. During the same period in the prior year, the company earned ($0.08) EPS.

A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Wedbush Securities Inc. grew its position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 70.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 145,000 shares of the company’s stock after acquiring an additional 60,000 shares during the quarter. Wedbush Securities Inc. owned 0.10% of Protalix Biotherapeutics worth $30,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Read More: Is the QQQ ETF safe?

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.